Our biosimilars pipeline

Fresenius Kabi is committed to providing valued biologic treatments through the development of new immunology and oncology pipeline therapies in our expanding biosimilars portfolio. 

Our pipeline includes biosimilars of adalimumab and tocilizumab in the autoimmune disease (immunology) therapy area, and a biosimilar of pegfilgrastim in the oncology therapy area.

In addition, we have multiple candidates in early-phase development, in both autoimmune and oncology therapy areas.

What kind of information on biosimilars is available? Learn here
 

FK/BIO/023/18 | February 2019